Maynard Um
-
-
-
-
-
-
-
Esperion Therapeutics' (ESPR) LDL-Lowering Drug Supported by KOLs - Citizens
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) Announces $210M Convertible Debt Financing
-
-
-
-
-
-
-
Esperion (ESPR) Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL and NEXLIZET
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

